Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate-Reference-Cited by-同舟云学术

Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate

Published:2017-08-01 Issue:11 Volume:83 Page:2377-2385
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Harrison Lester I.¹^ORCID,Sessions Victoria²,Wiggenhorn Christopher J.¹,Chalmers David³,Leung Pui⁴,Efthimiou John⁵

Affiliation:

1. Clinical and Biostatistics, Drug Delivery Systems Division; 3M Center; St Paul Minnesota USA

2. Clinical Programme Management; 3M Health Care Ltd; Loughborough Leicestershire UK

3. Data Sciences; Quotient Clinical; Edinburgh UK

4. Clinical Research; Quotient Clinical Ltd; Ruddington Nottingham UK

5. Independent Respiratory Consultancy, 5 Carey Close; Oxford UK

Funder

3M Company

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13349/fullpdf

Reference15 articles.

1. Guideline on the requirements for clinical documentation for orally inhaled products including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease in adults and for use in the treatment of asthma in children and adolescents

2. Systemic bioavailability of hydrofluoroalkane formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer;Clearie;Brit J Clin Pharm,2010

3. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients;Daley-Yates;J Aerosol Med Pulm Drug Deliv,2014

4. Formulation development of Sirdupla™ pMDI, a generic version of Seretide® Evohaler®;Slowey;Drug Deliv Lungs,2015

5. In-vitro and in-vivo development of Sirdupla™ (salmeterol/fluticasone propionate) pMDIs for Europe;Patel;Respir Drug Del,2016